Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
08 May 2009 - 12:43AM
PR Newswire (US)
NEW YORK, May 7 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.,
(NASDAQ: DCTH) a medical technology company testing its proprietary
Percutaneous Hepatic Perfusion (PHP(TM)) System for the treatment
of cancers of the liver, announced today that Eric D. Whitman, MD,
Director of the Atlantic Melanoma Center and a Principal
Investigator of Delcath's Phase III trial, will present at The 7th
World Congress on Melanoma, to be held in Vienna, Austria, May
12-16, 2009. (Logo:
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Dr.
Whitman's presentation, titled Percutaneous Isolated Hepatic
Perfusion for Cutaneous and Uveal Metastatic Melanoma, will discuss
his experience with the Delcath PHP System(TM), as part of
Delcath's multi-center Phase III trial for metastatic melanoma,
currently enrolling at twelve leading cancer centers throughout the
United States. This clinical study is testing the Delcath PHP
System(TM) for the regional delivery of melphalan to the liver to
treat patients with metastatic cutaneous and ocular melanoma who
have unresectable tumors in the liver. The Delcath PHP System(TM)
is designed to deliver significantly higher doses of anti-cancer
drugs to a patient's liver while minimizing entry of the drugs into
the rest of the patient's circulation. This isolation limits
toxicities which result from systemic chemotherapy treatments.
Patients in the Phase III trial are randomized into one of two
treatment arms, including immediate treatment with melphalan via
the Delcath PHP System(TM) or treatment with best alternative care.
The study is designed to evaluate the duration of tumor response in
each of the two study arms. Following guidelines established by
U.S. Food and Drug Administration under a Special Protocol
Assessment (SPA), patients are permitted to "cross-over" from the
best alternative care arm to receive treatment with the Delcath
System at the time of disease progression. Commenting on Dr.
Whitman's upcoming presentation, Richard L. Taney, President and
CEO of Delcath Systems, stated, "As we move towards full enrollment
of Delcath's pivotal Phase III Metastatic Melanoma Study,
increasing the awareness of the Delcath PHP System(TM) and its use
for metastatic melanoma becomes of even greater importance. We are
excited that Dr. Whitman will be sharing his experience with our
System at such a prestigious conference and with such an
international attendance. We look forward to more opportunities
such as these to continue informing the medical community about the
Delcath System." About the World Melanoma Congress The "World
Congress on Melanoma" and the "Congress of the European Association
of Dermato-Oncology" (EADO) have become major interdisciplinary
meetings for clinicians and basic scientists working in the
challenging fields of melanoma and non-melanoma skin cancer. For
the first time, both meetings will be held together as a Joint
Meeting covering the entire spectrum of cutaneous malignancies.
Clinicians and researchers will focus on the state of the art in
prevention, recognition, and treatment of cutaneous neoplasms
covering melanoma and non melanoma skin cancer as well as lymphomas
and rare skin tumors. About Delcath Systems, Inc. Delcath Systems,
Inc. is a medical technology company specializing in cancer
treatment. The Company is testing a proprietary, patented drug
delivery system for the treatment of liver cancers. Delcath's novel
drug delivery platform is testing the delivery of ultra-high doses
of anti-cancer drugs to the liver while preventing these high doses
of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical
studies for the treatment of liver cancers using high doses of
melphalan. The Company's intellectual property portfolio consists
of twenty-seven patents on a worldwide basis including the U.S.,
Europe, Asia and Canada. For more information, please visit the
Company's website at http://www.delcath.com/. The Private
Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf.
This news release contains forward-looking statements, which are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to,
uncertainties relating to our ability to successfully complete
Phase III clinical trials and secure regulatory approval of our
current or future drug-delivery system and uncertainties regarding
our ability to obtain financial and other resources for any
research, development and commercialization activities. These
factors, and others, are discussed from time to time in our filings
with the Securities and Exchange Commission. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to
reflect events or circumstances after the date they are made.
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO
http://photoarchive.ap.org/ DATASOURCE: Delcath Systems, Inc.
CONTACT: Robin Wagge, +1-212-843-8006, Web Site:
http://www.delcath.com/
Copyright